Mary Seger

753 total citations
21 papers, 571 citations indexed

About

Mary Seger is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Mary Seger has authored 21 papers receiving a total of 571 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Surgery and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Mary Seger's work include Diabetes Management and Research (10 papers), Diabetes Treatment and Management (9 papers) and Pancreatic function and diabetes (5 papers). Mary Seger is often cited by papers focused on Diabetes Management and Research (10 papers), Diabetes Treatment and Management (9 papers) and Pancreatic function and diabetes (5 papers). Mary Seger collaborates with scholars based in United States, Germany and United Kingdom. Mary Seger's co-authors include Helle Linnebjerg, Danny Soon, Ronald R. Bowsher, Prajakti A. Kothare, Malcolm I. Mitchell, David E. Coutant, Amparo de la Peña, Laiyi Chua, Shobha Reddy and Jeffrey D. Helterbrand and has published in prestigious journals such as Diabetes Care, Journal of Pharmaceutical Sciences and Clinical Pharmacology & Therapeutics.

In The Last Decade

Mary Seger

21 papers receiving 543 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary Seger United States 13 295 161 90 85 79 21 571
Elizabeth Rosolowsky Canada 10 270 0.9× 160 1.0× 144 1.6× 26 0.3× 104 1.3× 23 817
Ole Myking Norway 15 256 0.9× 115 0.7× 52 0.6× 50 0.6× 66 0.8× 33 586
Ian Craig Australia 9 224 0.8× 201 1.2× 26 0.3× 44 0.5× 40 0.5× 23 552
Kirtikumar D Modi India 16 317 1.1× 212 1.3× 97 1.1× 14 0.2× 82 1.0× 49 645
Sheon Mary United Kingdom 13 263 0.9× 57 0.4× 41 0.5× 30 0.4× 127 1.6× 31 668
Eleanor Dow United Kingdom 9 304 1.0× 284 1.8× 64 0.7× 17 0.2× 147 1.9× 16 756
H. Ditschuneit Germany 16 161 0.5× 407 2.5× 45 0.5× 31 0.4× 118 1.5× 58 801
Agostino Mallamace Italy 12 117 0.4× 78 0.5× 29 0.3× 16 0.2× 65 0.8× 27 491
J. A. Whitworth Australia 12 143 0.5× 65 0.4× 20 0.2× 34 0.4× 58 0.7× 33 500
Anna R. Dover United Kingdom 13 423 1.4× 220 1.4× 183 2.0× 18 0.2× 42 0.5× 29 606

Countries citing papers authored by Mary Seger

Since Specialization
Citations

This map shows the geographic impact of Mary Seger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Seger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Seger more than expected).

Fields of papers citing papers by Mary Seger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Seger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Seger. The network helps show where Mary Seger may publish in the future.

Co-authorship network of co-authors of Mary Seger

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Seger. A scholar is included among the top collaborators of Mary Seger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Seger. Mary Seger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Devanarayan, Viswanath, et al.. (2017). Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points. The AAPS Journal. 19(5). 1487–1498. 61 indexed citations
2.
Zhang, Xin, Mary Seger, David E. Coutant, et al.. (2017). LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels. Clinical Pharmacology in Drug Development. 6(6). 556–563. 13 indexed citations
3.
Linnebjerg, Helle, Mary Seger, David E. Coutant, et al.. (2016). Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus. Diabetes Obesity and Metabolism. 19(1). 33–39. 23 indexed citations
4.
Peña, Amparo de la, Mary Seger, Danny Soon, et al.. (2015). Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL. Clinical Pharmacology in Drug Development. 5(1). 69–75. 42 indexed citations
5.
6.
Seger, Mary, et al.. (2014). PO427 COMPARATIVE PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 INSULIN GLARGINE PRODUCTS, LY2963016 AND LANTUS® IN HEALTHY SUBJECTS AT 2 DOSE LEVELS. Diabetes Research and Clinical Practice. 106. S264–S264. 5 indexed citations
7.
8.
Zhang, Wei, et al.. (2012). QT effect of semagacestat at therapeutic and supratherapeutic doses. International Journal of Clinical Pharmacology and Therapeutics. 50(4). 290–299. 2 indexed citations
9.
Kothare, Prajakti A., Mary Seger, Justin Northrup, et al.. (2012). Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial. PubMed. 12(1). 8–8. 24 indexed citations
10.
Linnebjerg, Helle, Prajakti A. Kothare, Mary Seger, Anne M. Wolka, & Malcolm I. Mitchell. (2011). Exenatide – pharmacokinetics, pharmacodynamics, safety and tolerability in patients >= 75 years of age with Type 2 diabetes. International Journal of Clinical Pharmacology and Therapeutics. 49(2). 99–108. 23 indexed citations
11.
Linnebjerg, Helle, Mary Seger, Prajakti A. Kothare, et al.. (2011). A thorough QT study to evaluate the effects of singledose exenatide 10 μg on cardiac repolarization in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics. 49(10). 594–604. 30 indexed citations
12.
Peña, Amparo de la, Mary Seger, Klaus Rave, et al.. (2009). AIR Insulin Capsules of Different Dose Strengths May Be Combined to Yield Equivalent Pharmacokinetics and Glucodynamics. Diabetes Technology & Therapeutics. 11(s2). S–75. 5 indexed citations
13.
Benson, Charles, Mary Seger, & James R. Voelker. (2007). Inhibition of PKC β by Ruboxistaurin Does Not Enhance the Acute Blood Pressure Response to Nitroglycerin. Clinical Pharmacology & Therapeutics. 82(2). 181–186. 1 indexed citations
14.
Thalamas, Claire, Iris Rajman, Jaime Kulisevsky, et al.. (2005). Pergolide. Clinical Neuropharmacology. 28(3). 120–125. 12 indexed citations
15.
Rave, Klaus, Leszek Nosek, Amparo de la Peña, et al.. (2005). Dose Response of Inhaled Dry-Powder Insulin and Dose Equivalence to Subcutaneous Insulin Lispro. Diabetes Care. 28(10). 2400–2405. 64 indexed citations
16.
Skinner, Michael, Andrej Skerjanec, Mary Seger, et al.. (2003). Effect of age on the pharmacokinetics of duloxetine in women. British Journal of Clinical Pharmacology. 57(1). 54–61. 54 indexed citations
17.
Macias, William L., Jean-François Dhainaut, Sau Chi Betty Yan, et al.. (2002). Pharmacokinetic‐pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clinical Pharmacology & Therapeutics. 72(4). 391–402. 77 indexed citations
18.
Miličević, Zvonko, Smiljana Ristič, James R. Woodworth, et al.. (2001). Intramuscular injection of insulin lispro or soluble human insulin: pharmacokinetics and glucodynamics in Type 2 diabetes. Diabetic Medicine. 18(7). 562–566. 10 indexed citations
19.
Woodworth, James R., et al.. (1999). Pharmacokinetic and glucodynamic comparisons of recombinant and animal‐source glucagon after IV, IM, and SC injection in healthy volunteers. Journal of Pharmaceutical Sciences. 88(10). 991–995. 28 indexed citations
20.
Wanless, Ian R., et al.. (1982). Intrahepatic portal vein sclerosis in patients without a history of liver disease. An autopsy study.. PubMed. 106(1). 63–70. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elizabeth Rosolowsky Breakdown of academic impact, for papers by Ole Myking Breakdown of academic impact, for papers by Ian Craig Breakdown of academic impact, for papers by Kirtikumar D Modi Breakdown of academic impact, for papers by Sheon Mary Breakdown of academic impact, for papers by Eleanor Dow Breakdown of academic impact, for papers by H. Ditschuneit Breakdown of academic impact, for papers by Agostino Mallamace Breakdown of academic impact, for papers by J. A. Whitworth Breakdown of academic impact, for papers by Anna R. Dover
Rankless by CCL
2026